Coeptis Therapeutics Inc
Change company Symbol lookup
Select an option...
COEP Coeptis Therapeutics Inc
CLTS Earth Life Sciences Inc
CYBN Cybin Inc
LEN.B Lennar Corp
STLD Steel Dynamics Inc
GOEVW Canoo Equity Warrant Exp 21st Dec 2025 *W EXP 12/21/2025
GNBT Generex Biotechnology Corp
MFA MFA Financial Inc
GOOG Alphabet Inc
ADILW Adial Pharmaceuticals Equity Warrants Exp 31 July 2023 *W EXP 07/31/2023

Company profile

Coeptis Therapeutics, Inc. is a biopharmaceutical company. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The Company's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine, which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    2:45p ET 10/06/22
  • Last (size)
  • 52-Wk Range
    1.65 - 14.00
  • (01/11/22 - 09/23/22)
  • 202.0%
  • Market Cap
  • Shares Outstanding
  • -1.02
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • --
  • --

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.